Profile data is unavailable for this security.
About the company
BenevolentAI SA is an artificial intelligence (AI)-enabled drug discovery and development company. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, it delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers its in-house drug pipeline and supports collaborations with AstraZeneca, as well as research and charitable institutions. Its pipeline includes BEN-2293, BEN-8744, BEN-9160 and BEN-28010. It integrates data from across domains and data types, including omics, molecules, experiments, literature, pathology and biological systems to provide a holistic view of biology. BEN-8744 is under development as an ulcerative colitis treatment for a novel target discovered using its AI platform. BEN-2293 is a topical PanTrk inhibitor in development to relieve inflammation and rapidly resolve itch in patients with atopic dermatitis.
- Revenue in EUR (TTM)8.55m
- Net income in EUR-73.83m
- Incorporated2021
- Employees248.00
- LocationBenevolentAI SA4-8 Maple StreetLONDON W1T 5HDUnited KingdomGBR
- Websitehttps://www.benevolent.com/